Risk adjusted net present value: What is the current valuation of Pfizer’s (Clesacostat tromethamine + Ervogastat)?
(Clesacostat tromethamine + Ervogastat) is a small molecule commercialized by Pfizer, with a leading Phase II program in Metabolic Dysfunction-Associated Steatohepatitis (MASH).
(Clesacostat tromethamine + Ervogastat) is a small molecule commercialized by Pfizer, with a leading Phase II program in Metabolic Dysfunction-Associated Steatohepatitis (MASH).
What's Your Reaction?
